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Abstract
Background: Recent advances in molecular genetics have enabled to determine the genetic causes of non-syndromic
hearing loss, and more than 100 genes have been related to the phenotype. Due to this extraordinary genetic
heterogeneity, a large percentage of patients remain without any molecular diagnosis. This condition imply the
need for new methodological strategies in order to detect a greater number of mutations in multiple genes. In
this work, we optimized and tested a panel of 86 mutations in 17 different genes screened using a high-throughput
genotyping technology to determine the molecular etiology of hearing loss.
Methods: The technology used in this work was the MassARRAY iPLEX® platform. This technology uses silicon
chips and DNA amplification products for accurate genotyping by mass spectrometry of previous reported mutations.
The generated results were validated using conventional techniques, as direct sequencing, multiplex PCR and
RFLP-PCR.
Results: An initial genotyping of control subjects, showed failures in 20 % of the selected alterations. To optimize
these results, the failed tests were re-designed and new primers were synthesized. Then, the specificity and sensitivity
of the panel demonstrated values above 97 %. Additionally, a group of 180 individuals with NSHL without a molecular
diagnosis was screened to test the diagnostic value of our panel, and mutations were identified in 30 % of the cases. In
20 % of the individuals, it was possible to explain the etiology of the HL. Mutations in GJB2 gene were the
most prevalent, followed by other mutations in in SLC26A4, CDH23, MT-RNR1, MYO15A, and OTOF genes.
Conclusions: The MassARRAY technology has the potential for high-throughput identification of genetic
variations. However, we demonstrated that optimization is required to increase the genotyping success and
accuracy. The developed panel proved to be efficient and cost-effective, being suitable for applications involving the
molecular diagnosis of hearing loss.
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Background
Hearing loss (HL) is one of the most common sensory dis-
orders, affecting around one in a thousand individuals,
and can be caused by a variety of environmental and gen-
etic factors [1]. In recent years, there have been significant
advances in understanding the genetic causes of HL,
which has assisted in disease diagnosis and other clinical
practices.
Hereditary HL can be classified as syndromic or non-
syndromic. The syndromic type is associated with distinct-
ive clinical features and accounts for 30 % of congenital
hereditary HL. Hearing loss that occurs in the absence of
any other abnormal physical findings is known as non-
syndromic hearing loss (NSHL) and accounts for the
other 70 % [2–4].
More than 80 genes have been associated with NSHL
[5–8]. Due to this high genetic heterogeneity, there is
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still great difficulty in determining the molecular eti-
ology of HL. The most frequent genes associated with
autosomal recessive inheritance that have been identified
in NSHL are (in order of frequency) GJB2, SLC26A4,
MYO15A, OTOF, CDH23, and TMC1 [9, 10]. For each
of these genes, at least 20 mutations have been reported.
One specific mutation, c.35delG in the GJB2 gene, is the
most frequent in Caucasians, found in from 10 to 63 %
of homozygous NSHL cases [11, 12]. None of the genes
associated with non-syndromic autosomal dominant HL
are very frequent, although the most common are
WFS1, KCNQ4, COCH, and GJB2 [9].
Identification of hearing impairment is extremely im-
portant because it allows positive cases to be properly
referred for medical intervention and/or rehabilitation
programs, and enables genetic counseling of the fam-
ilies affected. The extreme genetic heterogeneity of
NSHL makes genetic diagnosis based on Sanger se-
quencing impractical, because this is a very expensive
and time-consuming technique, besides not being feas-
ible for genes with several exons. Thus, only a small
number of genes are currently screened for determining
the cause of HL, while a large percentage of patients re-
main without any genetic diagnosis. This indicates the
need for new methodological strategies for detection of
a greater number of mutations in multiple genes.
With the emergence of high-throughput technologies,
this gap is being filled due the possibility to perform
multiple simultaneous analyses, using small volumes of
samples and reagents in the reactions, combining high
accuracy with simplicity [13]. One of this promising
technologies is the MassARRAY® platform (Sequenom
Inc., San Diego, USA), that provides rapid measurement
of DNA products, with modest multiplexing and min-
imal assay setup costs due to the use of unmodified
oligonucleotide primers.
In order to address the genetic heterogeneity of HL and
the labor and expense of conventional techniques, we
developed a panel for diagnosis of non-syndromic hearing
loss based on genotyping of 86 of the most frequent
mutations that have already been described, using the
MassARRAY® iPLEX mass spectrometry system. The
power of the panel to detect mutations was demonstrated
by applying it to 180 patients with presumed NSHL.
Methods
Patient recruitment and assessment
The study was carried out at the Human Molecular
Genetics Laboratory of the Molecular Biology and
Genetic Engineering Center (CBMEG) of the University of
Campinas, in collaboration with the ENT department
of the University of Campinas Teaching Hospital
(São Paulo, Brazil). Blood samples were collected for
genetic testing after obtaining written informed consent.
The project was previously approved by the Research
Ethics Committee of the Faculty of Medical Sciences of
the University of Campinas (Report number 396/2006).
The technique was standardized using negative and
positive control samples from 25 affected individuals for
whom previous sequencing results were available for the
GJB2 gene and/or the SLC26A4 gene, and for the
m.1555A > G mitochondrial mutation in the MT-RNR1
gene. Additionally, analysis was made of 180 unrelated
Brazilian individuals with NSHL and without a molecular
diagnosis. Inclusion criteria were: (1) bilateral HL, (2) no
apparent syndromic features, (3) existence of audiometric
and physical examinations, (4) a complete history to rule
out obvious environmental causes of HL, and (5) onset of
HL at age <50 years.
Obvious environmental causes of HL identified by the
case history and physical examination included: prenatal
factors (measles and CMV infections, and exposure to
teratogenic agents during pregnancy), perinatal factors
(anoxia and prematurity/care in a neonatal intensive care
unit), postnatal factors (meningitis, otitis and head trauma),
and other clinical features (otosclerosis, osteogenesis imper-
fecta, Usher syndrome, and Ménière’s disease).
For those patients with postlingual HL, hearing loss se-
verity was defined according to pure-tone threshold hear-
ing levels: mild (26–40 dB); moderate (41–70 dB); severe
(71–90 dB); and profound (>90 dB) [14]. OAE, BERA, and
infant audiometric testing were used to diagnose children
with prelingual HL. All subjects were considered to have
moderate to profound bilateral sensorioneural HL.
Sample preparation
Genomic DNA was extracted from the leukocytes
present in 4–8 mL of peripheral blood. The extraction
was performed according to standard phenol-chloroform
protocols. The purity and concentration of the samples
were checked using a NanoDrop® 8000 spectrophotom-
eter (Thermo Scientific) and a Qubit® 2.0 fluorometer
(Invitrogen), respectively. Genomic DNA samples were
diluted to obtain a final concentration of 10 ng/μL.
The Sequenom MassARRAY® iPLEX platform
This technology uses silicon chips and DNA amplifica-
tion products for accurate genotyping by mass spec-
trometry. Genomic DNAs are submitted to iPLEX Gold
reaction and the product are transferred to chip wells by
a robot. The genotypes are detected in situ by using
matrix-assisted laser desorption ionization mass spec-
trometry (MALDI-TOF). This miniaturized method has
the potential for accurate, high-throughput, low-cost
identification of genetic variations [15].
The iPLEX Gold technology consists of an initial
locus-specific PCR reaction, followed by single base ex-
tension (SBE) using mass-modified dideoxynucleotide
Svidnicki et al. BMC Medical Genetics  (2015) 16:85 Page 2 of 11
terminators of an oligonucleotide primer, which anneals
immediately upstream of the polymorphic site of interest
(Fig. 1) [15]. The product of these reactions are directly
applied in a silicon chip. The mass of the extended pri-
mer is determined by means of MALDI-TOF mass spec-
trometry. The mass of the primer indicates the mutation
of interest and the mass of added bases indicate the al-
leles present at the polymorphic site. Sequenom supplies
a software (SpectroTYPER) that automatically translates
the mass of the observed primers into a genotype for
each reaction [16].
Mutation selection and assay design
After a bibliographic search for genetic alterations re-
lated to HL in different populations, 94 alterations in
17 genes were selected for development of the panel
(Table 1). The choice of genes to be studied was based
on the most important genes involved in HL [9]. All
these genes were described as affecting protein struc-
tures related to hearing, and were selected based on the
frequency of reported mutations.
The alterations in the GJB2 gene were selected based
on files for about 2500 individuals with HL, who had
been previously screened at Human Molecular genetics
Laboratory at CBMEG (Campinas/Brazil). For other
genes, mutations were selected based on how often they
were reported in the literature, and only mutations that
had been found in two or more families were included.
Regarding the OTOF, SLC26A4, and MYO15A genes, all
mutations that were identified in the Brazilian popula-
tion were selected [17–19]. To check all selected alter-
ations, see Additional file 1.
It was not possible to elaborate assays for the
del(GJB6-D13S1830) and del(GJB6-D13S1854) deletions
Fig. 1 Steps in genotyping using MassARRAY® iPLEX System. A schematic of the genotype reaction of an A-to-G SNP. a. Locus-specific amplification
reaction b. Treatment with SAP enzyme to neutralize unincorporated dNTPs. c. Locus-specific primer extension reaction (iPLEX assay). In this reaction,
an oligonucleotide primer anneals immediately upstream of the polymorphic site being genotyped, the primer and amplified target DNA
are incubated with mass-modified dideoxynucleotide terminators. The primer extension is made according to the sequence of the variant
site. d. The products of the reactions are spotted on a spectroCHIP. The CHIP is placed into the mass spectrometer and each spot is then
shot with a laser under vacuum by the matrix-assisted laser desorption ionization–time-of-flight (MALDI-TOF) method. A laser beam serves
as desorption and ionization source in MALDI mass spectrometry. Once the sample molecules are vaporized and ionized, they are transferred
electrostatically into a time-of-flight mass spectrometer (TOF-MS), where they individually detected. The mass of the extended primer is determined.
e. Sequenom supplies software that automatically translates the mass of the observed primers into a genotype for each reaction
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in the GJB6 gene, because the MassARRRAY spectrometry
technique presents a limitation to detect large delections/
insertions.
The sequences covering the selected alterations were
taken from the database of the National Center for
Biotechnology Information [http://www.ncbi.nlm.nih.gov/]
and Ensembl [http://www.ensembl.org/index.html]. Ampli-
fication and extension primers were designed using
MassARRAY Assay Design v. 4.0 software. To avoid inter-
action among the primers, the software divided the PCR
amplification and the Single Base Extension (SBE) into
multiplex reactions. At the end of the standardization, 86
assays functioned properly, and the mutations were divided
into 8 groups, containing 20, 18, 14, 9, 9, 8, 5 and 3 assays,
respectively.
Genotyping using the Sequenom MassARRAY® iPLEX
platform
The whole process was performed according to the manu-
facturer’s instructions for the multiplex reactions, in-
cluding the PCR amplification, the Shrimp Alkaline
Phosphatase (SAP) treatment, and the primer exten-
sion reactions using the iPLEX Gold assay (Sequenom
Inc., San Diego, USA). The reaction products were then
dispensed onto a 384-SpectroCHIP using the MassARRAY
nanodispenser and analyzed using the MassARRAY
platform. Mass signals for the different alleles were
captured with high accuracy by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS). Typer v. 4.0 (Sequenom Inc., San
Diego, USA) was used to process the raw data obtained
from the assays.
Specificity and sensitivity calculations
The calculations were made individually for 38 alterations
that had been previously detected in the control group.
Specificity is considered the proportion of true negatives
that are correctly identified by the test [20]. The calcula-
tion was made by the fraction of the genotypes who do
not have mutations (True Negatives) to those who truly
do not have mutations (True Negatives + False Positives).
Specificity ¼ TN
TN þ FP
Sensitivity is the proportion of true positives that are
correctly identified by the test [20]. Sensitivity is a frac-
tion of genotypes with mutations detected by the test
(True Positives) among those who actually have muta-
tions (True Positives + False Negatives)
Sensitivity ¼ TP
PT þ FN
Validation of the results
All samples were tested for the mutations c.35delG
and c.-23 + 1G >A (commonly known as IVS1 + 1G >A)
in the GJB2 gene, the mutations del(GJB6-D13S1830)
and del(GJB6-D13S1854) in the GJB6 gene, and the
m.1555A > G mutation in the MTRNR1 gene.
Table 1 Patterns of inheritance, genes and number of alterations selected for the panel
Inheritance Gene Locus No. of selected alterations OMIM Transcripts IDs
Autosomal recessive GJB2 DFNB1 22 121011 NM_004004
SLC26A4 DFNB4 14 605646 NM_000441
MYO15A DFNB3 5 602666 NM_016239
OTOF DFNB9 16 603681 NM_194248
CDH23 DFNB12 11 605516 NM_022124
TMC1 DFNB7/11 4 606706 NM_138691
TMPRSS3 DFNB8/10 5 605511 NM_024022
TRIOBP DFNB28 1 609761 NM_001039141
TMIE DFNB6 2 607237 NM_147196
DFNB59 DFNB59 1 610219 NM_001042702
Autosomal dominant GJB2 DFNA3 1 121011 NM_004004
WFS1 DFNA6/14 1 606201 NM_006005.3
KCNQ4 DFNA2 1 603537 NM_004700
COCH DFNA9 1 603196 NM_004086
TECTA DFNA8/12 4 602574 NM_005422
MIR-96 DFNA50 2 613074 NR_029512
Mitochondrial MT-RNR1 12S rRNA 2 561000 -
MT-TS1 tRNASer(UCN) 1 590080 -
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Allele-specific PCR was used to detect the c.35delG mu-
tation, as described elsewhere [21]. GJB2 mutations were
screened by direct sequencing of the coding region of the
gene [22, 23]. A multiplex PCR methodology was used to
detect del(GJB6-D13S1830) and del(GJB6-D13S1854) mu-
tations, according to the procedures reported previously
[24, 25]. Analysis of m.1555A >G was performed by PCR
amplification followed by digestion with the BsmAI re-
striction endonuclease [26]. To validate mutations found
in other genes, only the corresponding exon containing
the mutation was sequenced.
Results
Optimization
In the first genotyping using mass spectrometry of 15 con-
trol patients in triplicate, the genotyping call was calcu-
lated to be 74 %. Additionally, in all the control samples,
19 out of 94 mutations presented a failure.
In an attempt to improve the results, and minimize
the occurrence of primer interactions and incorrect pri-
mer annealing, we diminished the number of mutations
to be screened in each multiplex reaction, and the max-
imum number of mutations was limited to 20 for each
well. In addition, the extension primers of all the 19 re-
actions that failed were redesigned in reverse sequences
using the MassARRAY Assay Design software. This re-
sulted in a greater number of groups of multiplex reac-
tions (eight rather than six) used to analyze all the 94
mutations in each patient.
After optimization, new screening of 25 individuals
of the control group was performed indicating that the
genotyping call rate of the technique increased to
91 % and the sensitivity and specificity of the panel
exceeded 97 %. These calculations were made compar-
ing results of 38 mutations previously analyzed by
Sanger sequencing with those results obtained by
MassARRAY (Table 2). Following primer redesign, of
19 assays that were not working, 11 assays started to
function properly, but 8 assays still failed (Table 3). In
seven of these assays, no allele was detected, and one
assay (p.V153I in the GJB2 gene) continued to show
false negative results, even after redesigning the extension
primer. These eight mutations were excluded from the
panel and were not considered in subsequent analyses.
Mutation screening
After standardizing the panel with 86 mutations, this set
of variants was screened using the mass spectrometry
system in a group of 180 individuals with moderate to
profound non-syndromic HL. The technique identified
genetic alterations in seven genes in a total of 54 individ-
uals (Table 4). Mutations in the GJB2 gene were found
in 43 cases, with c.35delG being the most prevalent,
identified in at least one allele in 28 individuals. The
gene with the second largest number of mutations de-
tected by mass spectrometry in our sample was SLC26A4,
with p.V609G being the most frequent variant (detected
in four cases). Mutations in the MT-RNR1, MT-TS1,
OTOF, MYO15A, and CDH23 genes were also identified.
A comparison of the results obtained by mass spec-
trometry and conventional techniques is provided in
Table 4, where the alterations shown in bold type were
only detected by the conventional techniques because
they were not included in the panel.
The c.10573delA mutation in MYO15A gene was
identified in one patient by mass spectrometry. How-
ever, the Sanger sequencing revealed a different alter-
ation at the same site, c.10573A > G (p.S3525G). This
occurred because iPLEX MassARRAY® technique de-
tects only one base after the extension primer binding
region, and for both alterations the base was a guanine
instead of an adenine. The c.10573delA mutation cor-
responds to the deletion of an adenine, and the next
base in the sequence is a guanine. In the case of the
p.S3525G mutation, a substitution of the adenine for a
guanine occurs at the same site. The p.S3525G alteration
has been reported as a single nucleotide variation (SNV),
according to the National Center for Biotechnology Infor-
mation [http://www.ncbi.nlm.nih.gov/], and no data of
clinical significance was available. To assess the possible
damaging effect of amino acid substitution, four differ-
ent in silico software analyses were used: SIFT [http://
sift.jcvi.org/]; PolyPhen [http://www.polyphen.com];
Align-GVGD [http://agvgd.iarc.fr/]; and Mutation Taster
Table 2 Comparison of genotyping results of 38 alterations
obtained by MassARRAY® iPLEX system before and after
optimization of the panel
TP FP TN FN GC SP SN
Before optimization (%) 3.2 3.1 93.23 0.47 74 97 87
After optimization (%) 4.04 1.96 93.89 0.12 91 98 97
TP True positives, FP False positives, TN True negatives, FN False negatives,
GC Genotyping Call, SP Specificity, SN Sensitivity
Table 3 Mutations that failed and had the assays excluded of
the panel
Gene Alteration Protein change
GJB2 c.283G > A p.V95M
GJB2 c.457G > A p.V153I
MYO15A c.6796G > A p.V2266M
OTOF c.2122C > T p.R708*
TMPRSS3 c.1221C > T p.P404L
TECTA c.3107G > A p.C1036Y
TMIE c.241C > T p.R81C
CDH23 c.6133G > A p.D2045N
*translation termination (stop) codon.
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[http://www.mutationtaster.org]. In all analyses, the effect
was damaging for the myosin XV protein.
The genotyping cost using the developed panel to screen
4128 reactions is US$ 950 per SpectroCHIP (Table 5).
Then, the cost per reaction (SNP/mutation) is approxi-
mately US$ 0.23. Taking into consideration that our panel
uses eight wells per patient, it is possible to genotype 48 pa-
tients in a single 384-SpectroCHIP. Therefore, the costs per
patient, including materials and reagents, is approximately
US$ 20. These values do not include the labor, equipment
costs, maintenances, and operational expenditure.
Discussion
The MassARRAY iPLEX technology has the potential
for high-throughput identification of genetic variations;
however, our results demonstrated that to increase the
genotyping success and accuracy, the optimization is re-
quired. After redesigning the assays that failed in the ini-
tial tests and genotyping control samples, sensitivity of
the technique raised from 87 % to 97 %, the specificity
increases from 97 % to 98 % and genotyping call rate in-
creases from 74 % to 91 %.
Table 4 Molecular alterations detected in 180 individuals
No. of cases Alterations detected Gene(s) Onset Severity
20 c.35delG/c.35delG GJB2 Prelingual Severe/profound
3 p.V27I/wt GJB2 Prelingual/postlingual Moderade/profound
2 c.35delG/wt GJB2 Postlingual Moderade/profound
2 p.M34T/wt GJB2 Prelingual/postlingual Moderade/profound
2 p.V609G/wt SLC26A4 Prelingual/postlingual Severe/profound
2 m.1555A > G MT-RNR1 Postlingual Moderade/profound
1 c.35delG/wt; ΔGJB6-D13S1830/wt GJB2; GJB6 Prelingual Profound
1 c.35deG/p.L90P GJB2 Postlingual Moderade
1 c.35delG/c.-23 + 1G > A GJB2 Prelingual Profound
1 c.35delG/c.167delT GJB2 Prelingual Moderade-severe
1 c.35delG/p.W172* GJB2 Prelingual Profound
1 p.35delG/p.M34T GJB2 Postlingual Moderade
1 p.E47*/wt; ΔGJB6-D13S1830/wt GJB; GJB6 Prelingual Profound
1 p.K168R/wt GJB2 Postlingual Profound
1 p.M34T/p.V37I GJB2 Postlingual Moderade
1 p.L90P/wt GJB2 Postlingual Moderade
1 p.V37I/p.V95M GJB2 Postlingual Profound
1 p.R184P/c.35delG GJB2 Prelingual Profound
1 p.V27I/p.E114G GJB2 Postlingual Moderade
1 p.W24*/p.W24* GJB2 Postlingual Profound
1 p.R75Q/wt GJB2 Postlingual Moderade
1 p.V27I/wt; p.V609G/wt GJB2; SLC26A4 Postlingual Profound
1 p.V138F/wt SLC26A4 Postlingual Profound
1 p.V609G/wt; c.5800_5801dupC/wt SLC26A4; OTOF Postlingual Profound
1 p.R776C/wt SLC26A4 Postlingual Profound
1 p.R1746Q/wt CDH23 Postlingual Moderade
1 m.7445A > G MT-TS1 Prelingual Profound
1 p.S3525G/wt MYO15A Prelingual Profound
1 ΔGJB6-D13S1854/wt GJB6 Postlingual Moderade
wt wild type. *translation termination (stop) codon. Alterations in bold were detected by conventional techniques
Table 5 Costs in dollars to genotype a set of 86 alterations
related to NSHL using the MassARRAY® iPLEX System
Materials/reagents Cost per chip Cost per patient
Chips and kits sequenom US$ 800.00 US$ 16.7
Primers US$ 100.00 US$ 2.08
Consumables US$ 50.00 US$ 1.04
Total US$ 950.00 US$ 19.8
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Studies that have screened multiple mutations simultan-
eously in a substantial number of patients are scarce in
the literature. In this study, the etiology of NSHL was in-
vestigated in a sample of 180 Brazilian individuals. These
patients were selected carefully, and those cases with pos-
sible environmental etiology or with clinical features not
compatible with sensorineural NSHL, were excluded.
After screening by mass spectrometry, we identified mu-
tations in 32 patients with prelingual HL, and 22 patients
with postlingual HL, totaling 54 patients. 32 out of 54 pa-
tients, (59.3 %) had family history of HL. Among the 17
genes analyzed, mutations were identified in seven of
them, five autosomal (GJB2, SLC26A4, MYO15A, OTOF,
and CDH23) and two mitochondrial (MT-RNR1 and MT-
TS1). The results indicated a predominance of mutations
in connexin 26 (GJB2), in concordance with previous
works [9, 23–25, 27].
The c.35delG mutation in the GJB2 gene was identified
in 15.6 % of the patients, and in 11.1 % of cases, this muta-
tion was found in homozygosis, explaining the etiology of
deafness. All of the individuals that were homozygous for
this mutation had profound prelingual HL. The molecular
identification of the c.35delG is usually made by allele-
specific PCR or PCR followed by enzymatic restriction.
These reactions are relatively inexpensive and are recom-
mended as the first genetic test performed.
Other mutations in the GJB2 gene were identified by
mass spectrometry in 20 of the analyzed patients. To de-
tect GJB2 mutations, the coding exon of this gene is
usually sequenced. As Sanger sequencing is expensive
and time consuming, mass spectrometry offers an useful
alternative procedure.
Mutations in the SLC26A4 gene are the second most
frequent cause of NSHL [9]. We identified six individ-
uals with three different mutations in this gene. The
p.V609G variant was the most prevalent, found in four
individuals (2.2 % of the sample population). Functional
studies have demonstrated that there is a partial loss of
protein activity when this alteration is present, indicating
a potential pathogenic effect, especially if associated with
other genetic or environmental factors [28]. In all the
four individuals, the p.V609G was identified in only one
allele of the gene, so the cause of HL was not elucidated.
The SLC26A4 gene has 21 exons, so it would be expen-
sive to perform a routine sequencing of all of them.
Therefore, genotyping the selected set of mutations with
mass spectrometry could be a useful option for initial
analysis of this gene.
The del(GJB6-D13S1830) and del(GJB6-D13S1854) de-
letions in the GJB6 gene [24, 25], could not be included
in our panel. However, these mutations were screened in
all patients, as was previously described. The del(GJB6-
D13S1854) deletion was found in one heterozygous indi-
vidual, and compound heterozygous genotypes involving
del(GJB6-D13S1830) and GJB2 mutations were identified
in two individuals.
Three other mutations: p.R1746Q, c.5800_5801dupC,
and p.S3525G, were identified in heterozygous genotypes,
in the genes CDH23, OTOF, and MYO15A, respectively.
These mutations do not explain the etiology of HL because
they segregate with autosomal recessive inheritance. In sub-
sequent studies, it would be necessary to sequence these
genes in an attempt to find mutations in the second allele
that could explain the cause of HL in these individuals.
The p.S3525G (c.10573A >G) mutation in the MYO15A
gene was identified here by Sanger sequencing. No sig-
nificant clinical data were available for this alteration,
so in silico analyses were performed using four different
software packages in order to assess the possible dam-
aging effect of amino acid substitution. All these ana-
lyses indicated protein damage as an outcome. It is
possible that this alteration contributes to hearing loss
if it is present in both alleles or associated with other
mutation in MYO15A.
Two mutations in mitochondrial genes were identified:
m.1555A > G in MT-RNR1, detected in two individuals,
and m.7445A > G in MT-TS1, detected in one case. Ac-
cording to previous studies, m.1555A > G is a common
cause of genetic HL in Brazil. It was found in approxi-
mately 2 % of unselected cases of HL, and it was recom-
mended for the inclusion in molecular diagnostic testing
for HL [29, 30]. Early identification of patients with HL
due to mutations in mitochondrial DNA can influence
genetic counseling regarding maternal inheritance, en-
able avoidance of known risk factors, and assist pharma-
cological strategies for the prevention or reduction of
HL progression [31].
Taking into account our data and the need to minimize
costs and time, a pipeline trial is recommended before
proceeding with mutations analysis using high-throughput
methods. The first step should be to evaluate the clinical
history of the patient in order to exclude obvious environ-
mental etiologies. The second one is to assess the age of
onset and the degree of HL. In cases of prelingual HL, it is
recommend screening for the c.35delG mutation and
GJB6 deletions by conventional techniques, due to the
high frequency of these mutations as a cause of prelingual
HL. For the remaining cases where molecular diagnosis is
unclear, as well as cases of postlingual HL, the screening
for the main mutations involved in HL by high through-
put or conventional methods is recommended.
The genetic evaluation identified mutations in 30 % of
the analyzed patients, and emphasized the importance of
molecular testing, however in only 20 % of the cases the
etiology of HL was concluded. The high number of cases
with unknown etiology was possibly due to the broad
genetic heterogeneity involved in NSHL, and also to the
selection of mutations made to this study, since this
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selection was based on studies of other populations, includ-
ing countries with high rates of consanguineous marriages,
and might not be representative of the Brazilian population.
The continuous advances in DNA sequencing tech-
nologies allowed us to identify genetic alterations in a
growing number of individuals. Therefore, they enabled
the identification of the most frequent mutations in dif-
ferent populations. With this knowledge, the screening
of specific mutations by high-throughput technologies
could be really interesting to use in routine tests, since
panels with specific assays could be customized for
each population, reducing costs and enabling the rapid
screening of a large number of patients.
There are several reliable, relatively simple and inexpen-
sive methods currently in use to detecting mutations. Re-
cently, array-based tests have been developed for NSHL,
using different genotyping technologies: APEX microarray
[32], designed Affymetrix resequencing microarrays [33]
and TaqMan® OpenArray™ [34]. All these technologies
have in common the use of oligonucleotides applied on a
solid surface and fluorescent compounds. The OpenArray
and APEX array focus specifically on the detection of
previously reported mutations, whereas the Affymetrix
resequencing array allows for the discovery of new muta-
tions. The APEX microarray allows some versatility, since
it is possible add SNPs after ordering the custom test. In
contrast, OpenArray and resequencing arrays do not allow
for modifications after achievement of the plates/chips.
With reference to costs, the screening of mutations with
Affymetrix resequencing arrays are quite high in compari-
son with the others, making it unfeasible the use of this
technique in a routine laboratory setting [35, 36].
In contrast to these technologies, the MassARRAY iPLEX
does not uses fluorescent compounds, and analyses direct
DNA products. As the OpenArray and APEX, this tech-
nique has the limitation of detect only previously reported
mutations. However, the great advantage of MassARRAY
iPLEX is the versatility and flexibility, since the assays are
not pre-spotted into the chip by the manufacturer. There-
fore, you can easily add or remove tests and genotyping dif-
ferent sets of mutations on the same chip. Moreover, the
number of wells analyzed at a time can be variable, since
the same chip can be used in different experiments.
All the techniques mentioned above, including
MassARRAY, need be confirmed by other techniques
when mutations were found. Our results demonstrated
that even after optimization, false positive results were
observed in 1.96 % of the genotypes. Therefore, the val-
idation of positive cases must be carried out to ensure
the reliability of the results.
Sanger sequencing is considered the golden standard
for mutation identification due to its accuracy. How-
ever, Sanger sequencing is labor intensive and has high
per-base sequencing costs. It can be effectively only if
used to screen genes with a limited number of exons, or
to confirm mutations found with other technologies.
Next generation sequencing is the most efficient method
to identify mutations, especially in heterogeneous disor-
ders such as hereditary hearing loss. Recent developments
in NGS and DNA capture technologies provide a potential
approach for accurate molecular diagnosis of HL [37–39].
The main advantage of NGS over current diagnostic
methods is that a significantly higher rate of successful
diagnosis can be obtained by screening both known and
novel mutations in all HL genes simultaneously. However,
its high cost and delay in data analysis make it impractical
for application in the diagnosis of many individuals.
The high-throughput techniques such as IPLEX
MassARRAY® system is a good option for initial screen-
ing of the most frequent mutations, since it enables
genotyping a substantial set of known alterations simul-
taneously, in shorter periods of time, and at lower cost,
compared to the screening of the main mutations per-
formed with conventional techniques like PCR, Sanger
sequencing and enzymatic restriction. The cost of con-
ventional routine screening of mutations in the GJB2,
GJB6, and MT-RNR1 genes for diagnosis of hearing loss
is approximately US$ 30 per patient. In contrast, the
cost of mass spectrometry screening of 86 genetic muta-
tions in nine genes is approximately US$ 20 per patient,
evidencing, this way, a better cost-benefit. This compari-
son only include the costs of reagents and materials used
in our research laboratory.
Conclusions
We have developed and tested a panel based on Mas-
sARRAY technology for screening 86 mutations related
to NSHL. This technology has the potential for high-
throughput identification of genetic variations; however,
we demonstrated that to increase the genotyping success
and accuracy, optimization is required. The panel proved
to be cost-effective and efficient, due to the high values
obtained in sensitivity and specificity. We tested the
panel in affected Brazilian individuals with NSHL with-
out a molecular diagnosis. Genetic alterations were iden-
tified in 30 % of them, and the etiology of NSHL was
concluded in 20 % of the cases. These results demon-
strate that the developed panel is suitable and helpful to
be applied in the diagnosis of hearing loss.
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